Asset Management One’s Myriad Genetics MYGN Stock Holding History

Asset Management One’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-5,970	Closed	-$176K	–	1107
2018 Q1	$176K	Buy	+5,970	New	+$202K	﹤0.01%	1024
2016 Q4	–	Sell	-195,351	Closed	-$4.02M	–	1131
2016 Q3	$4.02M	Buy	+195,351	New	+$4.95M	0.06%	376
2016 Q1	–	Sell	-12,931	Closed	-$558K	–	1333
2015 Q4	$558K	Buy	+12,931	New	+$546K	0.01%	1046

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Asset Management One's MYGN Position: Q2 2018 in Review

Asset Management One sold out of Myriad Genetics (MYGN) in Q2 2018, closing a stake of 5,970 shares — an estimated $176K sold.

Asset Management One first reported a position in MYGN in Q4 2015 and held it in 3 quarters. The position peaked at $4.02M in Q3 2016. 258 funds tracked by Wall St. Rank hold MYGN as of Q2 2018.

Asset Management One reported no remaining Myriad Genetics position as of Q2 2018 after selling out during the quarter.
Asset Management One sold 5,970 Myriad Genetics shares in Q2 2018, an estimated $176K.
Asset Management One first reported a position in Myriad Genetics in Q4 2015 and held it in 3 quarters.
Asset Management One's Myriad Genetics position peaked at $4.02M in Q3 2016.
258 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2018.

Based on Asset Management One's 13F filing for Q2 2018, filed 14 Aug 2018.